<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39315343</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2054-3581</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Canadian journal of kidney health and disease</Title><ISOAbbreviation>Can J Kidney Health Dis</ISOAbbreviation></Journal><ArticleTitle>Cannabis Use, Perspectives, and Experiences Among Patients Receiving Hemodialysis: A Descriptive Patient Survey.</ArticleTitle><Pagination><StartPage>20543581241274002</StartPage><MedlinePgn>20543581241274002</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20543581241274002</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/20543581241274002</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Patients with chronic kidney disease experience high burden of symptoms, negatively affecting their quality of life. Medication therapy is often initiated to address these symptoms but is limited by variable efficacy and high pill burden. There is interest among clinicians and patients to explore cannabis and cannabinoids as an alternative treatment to manage symptoms related to kidney disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The objectives were to characterize cannabis use among patients receiving maintenance hemodialysis (HD), to describe patient perspectives on cannabis, and to explore patient experiences with their kidney health care team related to cannabis.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">This was a descriptive, cross-sectional paper-based patient survey.</AbstractText><AbstractText Label="SETTING/PARTICIPANTS" NlmCategory="UNASSIGNED">Patients receiving maintenance HD at Toronto General Hospital in the ambulatory setting between July and August 2020 were included.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A 33-item questionnaire was developed to address the study questions based on existing cannabis questionnaires and input from kidney specialist physicians, pharmacists, kidney nurse practitioners, and patients. The questionnaire was distributed to patients during their in-center HD session. Patients who chose to participate in the study completed the questionnaire and returned it to the study team.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In total, there were 52 respondents, of which 11 (21%) reported cannabis use in the preceding 3 months, and 23 (44%) reported historical cannabis use. Baseline characteristics were similar between those who used cannabis and those who did not, with a possible trend of cannabis users being younger. The most commonly reported reasons for using cannabis were recreation and symptom management. Those who reported using cannabis for symptom management were doing so without medical authorization or documentation. Common symptoms that cannabis was used to self-treat were insomnia, anxiety, and/or non-neuropathic pain. Dried flower was the most common type of product used, and smoking was the most common route. Care gaps and opportunities to improve patient care related to cannabis use were identified, related to monitoring and management of adverse effects, management of drug interactions, harm reduction strategies, informed decision-making, and prescriber education.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="UNASSIGNED">The overall participation rate was low, at approximately 17%, possibly related to the COVID-19 pandemic, lack of interest, or fear of revealing cannabis use. Non-response bias is a possible limitation as this was a voluntary survey. The questionnaire was limited to multiple-choice and Likert scale questions, therefore limiting the depth of patient responses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Our study showed that cannabis use among patients receiving HD is common and comparable with the general population. Patients may be using cannabis to self-manage symptoms related to kidney disease, without the involvement of the health care team. Multiple opportunities to improve patient care related to cannabis use were identified.</AbstractText><CopyrightInformation>© The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0002-2919-6660</Identifier><AffiliationInfo><Affiliation>University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Battistella</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9456-4365</Identifier><AffiliationInfo><Affiliation>University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Can J Kidney Health Dis</MedlineTA><NlmUniqueID>101640242</NlmUniqueID><ISSNLinking>2054-3581</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="fre"><AbstractText Label="CONTEXTE" NlmCategory="UNASSIGNED">Les symptômes liés à l’insuffisance rénale représentent un lourd fardeau pour les patients qui en sont atteints, ce qui affecte négativement leur qualité de vie. Un traitement médicamenteux est souvent prescrit pour soulager les symptômes, mais il est limité par son efficacité variable et le nombre élevé de médicaments. Les patients et les cliniciens sont ouverts à explorer d’autres avenues pour gérer les symptômes de l’insuffisance rénale, notamment la consommation de cannabis et de cannabinoïdes.</AbstractText><AbstractText Label="OBJECTIFS" NlmCategory="UNASSIGNED">Caractériser la consommation de cannabis chez les patients recevant des traitements d’hémodialyse (HD) chronique; décrire les perspectives des patients sur le cannabis et examiner les expériences des patients avec leurs équipes de soins en lien avec la consommation de cannabis.</AbstractText><AbstractText Label="TYPE D’ÉTUDE" NlmCategory="UNASSIGNED">Enquête transversale descriptive sous forme d’un questionnaire papier remis aux patients.</AbstractText><AbstractText Label="CADRE ET SUJETS DE L’ÉTUDE" NlmCategory="UNASSIGNED">Les patients qui suivaient des traitements d’HD chronique en ambulatoire à l’Hôpital général de Toronto en juillet et août 2020.</AbstractText><AbstractText Label="MÉTHODOLOGIE" NlmCategory="UNASSIGNED">Pour répondre aux objectifs de l’étude, un questionnaire en 33 points a été élaboré à partir de questionnaires existants sur la consommation de cannabis et des commentaires de néphrologues, pharmaciens, infirmières praticiennes en néphrologie et patients. Le questionnaire a été distribué aux patients pendant une séance d’HD en centre. Les personnes qui ont choisi de participer à l’étude l’ont rempli et l’ont renvoyé à l’équipe de recherche.</AbstractText><AbstractText Label="RÉSULTATS" NlmCategory="UNASSIGNED">En tout, 52 personnes ont répondu au questionnaire, desquelles 11 (21%) ont déclaré avoir consommé du cannabis dans les trois mois précédents et 23 (44%) en avoir consommé dans le passé. Les caractéristiques initiales des consommateurs de cannabis étaient semblables à celles des personnes qui n’en consommaient pas; les consommateurs de cannabis ayant tendance à être plus jeunes. On consommait principalement du cannabis pour le côté récréatif et pour gérer les symptômes. Les personnes qui consommaient du cannabis pour gérer leurs symptômes le faisaient sans documentation ou indication médicale. Le cannabis était consommé pour l’auto-traitement de symptômes courants comme l’insomnie, l’anxiété et/ou la douleur non neurogène. Le plus souvent, le cannabis était fumé, et la fleur séchée était le produit le plus utilisé. Des lacunes dans les soins et des occasions d’améliorer les soins aux patients ont été identifiées en lien avec la consommation de cannabis, celles-ci concernaient la surveillance et la gestion des effets indésirables, la gestion des interactions médicamenteuses, les stratégies de réduction des risques, la prise de décisions éclairées et l’éducation des prescripteurs.</AbstractText><AbstractText Label="LIMITES" NlmCategory="UNASSIGNED">Le taux de participation global a été faible (environ 17%), possiblement en raison de la pandémie de COVID-19, d’un manque d’intérêt ou de la réticence à révéler la consommation de cannabis. La participation était volontaire, un biais de non-réponse est donc possible. Le questionnaire n’était constitué que de questions à choix multiples et à échelle de Likert, ce qui limite la profondeur des réponses.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Notre étude montre que la consommation de cannabis chez les patients sous HD est courante et comparable à celle de la population générale. Les patients peuvent consommer du cannabis pour soulager les symptômes liés à l’insuffisance rénale sans intervention de l’équipe de soins. Le sondage a permis d’identifier plusieurs occasions d’améliorer les soins aux patients en lien avec la consommation de cannabis.</AbstractText><CopyrightInformation>© The Author(s) 2024.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cannabis</Keyword><Keyword MajorTopicYN="N">hemodialysis</Keyword><Keyword MajorTopicYN="N">kidney disease</Keyword><Keyword MajorTopicYN="N">survey</Keyword><Keyword MajorTopicYN="N">symptoms</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>4</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39315343</ArticleId><ArticleId IdType="pmc">PMC11418350</ArticleId><ArticleId IdType="doi">10.1177/20543581241274002</ArticleId><ArticleId IdType="pii">10.1177_20543581241274002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almutary H, Bonner A, Douglas C. Which patients with chronic kidney disease have the greatest symptom burden? A comparative study of advanced CKD stage and dialysis modality. J Ren Care. 2016;42(2):73-82.</Citation><ArticleIdList><ArticleId IdType="pubmed">26936486</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturgill D, Bear A. Unique palliative care needs of patients with advanced chronic kidney disease: the scope of the problem and several solutions. Clin Med (Lond). 2019;19(1):26-29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6399628</ArticleId><ArticleId IdType="pubmed">30651241</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089-1096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689877</ArticleId><ArticleId IdType="pubmed">19423571</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho C, Martinusen D, Lo C. A review of cannabis in chronic kidney disease symptom management. Can J Kidney Health Dis. 2019;6:9828391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6388458</ArticleId><ArticleId IdType="pubmed">30828459</ArticleId></ArticleIdList></Reference><Reference><Citation>Rein JL. The nephrologist’s guide to cannabis and cannabinoids. Curr Opin Nephrol Hypertens. 2020;29(2):248-257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012334</ArticleId><ArticleId IdType="pubmed">31972598</ArticleId></ArticleIdList></Reference><Reference><Citation>Park F, Potukuchi PK, Moradi H, et al.. Cannabinoids and the kidney: effects in health and disease. Am J Physiol Renal Physiol. 2017;13(5):F1124-F1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792153</ArticleId><ArticleId IdType="pubmed">28747360</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillig KW, Mahlberg PG. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am J Bot. 2004;91(6):966-975.</Citation><ArticleIdList><ArticleId IdType="pubmed">21653452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton CH. Pharmacology and effects of cannabis a brief review. Br J Psychiatry. 2001;178:101-106.</Citation><ArticleIdList><ArticleId IdType="pubmed">11157422</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramovici H. Information for Health Care Professionals: Cannabis (Marihuana, Marijuana) and the Cannabinoids. Ottawa, ON, Canada: Health Canada; 2018.</Citation></Reference><Reference><Citation>Chang AE, Shiling DJ, Stillman RC, et al.. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: a prospective, randomized evaluation. Ann Intern Med. 1979;91(6):819-824.</Citation><ArticleIdList><ArticleId IdType="pubmed">293141</ArticleId></ArticleIdList></Reference><Reference><Citation>Duran M, Pérez E, Abanades S, et al.. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70(5):656-663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997305</ArticleId><ArticleId IdType="pubmed">21039759</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith LA, Azariah F, Lavender V, et al.. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochr Datab Syst Rev. 2015;2015(11):CD009464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6931414</ArticleId><ArticleId IdType="pubmed">26561338</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams DI, Jay CA, Shade SB, et al.. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515-521.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296917</ArticleId></ArticleIdList></Reference><Reference><Citation>Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl). 2005;181(1):170-178.</Citation><ArticleIdList><ArticleId IdType="pubmed">15778874</ArticleId></ArticleIdList></Reference><Reference><Citation>Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat. 2005;13(2):97-103.</Citation><ArticleIdList><ArticleId IdType="pubmed">16324422</ArticleId></ArticleIdList></Reference><Reference><Citation>
Minister of Justice. An act respecting cannabis and to amend the controlled drugs and substances act, the Criminal Code and Other Acts. House of Commons of Canada. Published 2018. https://laws-lois.justice.gc.ca/PDF/C-24.5.pdf. Accessed October 23, 2019.</Citation></Reference><Reference><Citation>
Health Canada. Canadian cannabis survey 2023: summary. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/canadian-cannabis-survey-2023-summary.html#s2-2 Published 2024. Accessed April 21, 2024.</Citation></Reference><Reference><Citation>Samaha D, Kandiah T, Zimmerman D. Cannabis use for restless legs syndrome and uremic pruritus in patients treated with maintenance dialysis: a survey. Can J Kidney Health Dis. 2020;7:954944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488602</ArticleId><ArticleId IdType="pubmed">32963792</ArticleId></ArticleIdList></Reference><Reference><Citation>Collister D, Herrington G, Delgado L, et al.. Patient views regarding cannabis use in chronic kidney disease and kidney failure: a survey study. Nephrol Dial Transplant. 2023;38:922-931.</Citation><ArticleIdList><ArticleId IdType="pubmed">35881478</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison J, Abbey S, Badr S, et al.. Anonymous Survey on Marijuana Use in the Transplant Clinic. University Health Network Internal Protocol; (unpublished); 2015. Toronto, Ontario, Canada.</Citation></Reference><Reference><Citation>Gardiner KM, Singleton JA, Sheridan J, et al.. Health professional beliefs, knowledge, and concerns surrounding medical cannabis: a systematic review. PLoS ONE. 2019;14(5):e0216556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6502454</ArticleId><ArticleId IdType="pubmed">31059531</ArticleId></ArticleIdList></Reference><Reference><Citation>St. Pierre M, Matthews L, Walsh Z. Cannabis education needs assessment among Canadian physicians-in-training. Complement Ther Med. 2020;49:102328.</Citation><ArticleIdList><ArticleId IdType="pubmed">32147035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng JY, Gilotra K, Usman S, Chang Y, Busse JW. Attitudes toward medical cannabis among family physicians practising in Ontario, Canada: a qualitative research study. CMAJ Open. 2021;9(2):E342-E48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084545</ArticleId><ArticleId IdType="pubmed">33849983</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitau K, Howe H, Ginsberg L, et al.. Therapeutic cannabis use in kidney disease: a survey of Canadian nephrologists. Kidney Med. 2020;4(5):100453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9065896</ArticleId><ArticleId IdType="pubmed">35518836</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake PG. Global dialysis perspective: Canada. Kidney360. 2020;1(2):115-118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8809102</ArticleId><ArticleId IdType="pubmed">35372909</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotermann M. Looking back from 2020, how cannabis use and related behaviours changed in Canada. Health Rep. 2021;32(4):30-14.</Citation><ArticleIdList><ArticleId IdType="pubmed">33881274</ArticleId></ArticleIdList></Reference><Reference><Citation>Black N, Stockings E, Campbell G, et al.. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995-1010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949116</ArticleId><ArticleId IdType="pubmed">31672337</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer B, Russell C, Sabioni P, et al.. Lower-risk cannabis use guidelines (LRCUG): an evidence-based update. Am J Public Health. 2017;107(8):e1-e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508136</ArticleId><ArticleId IdType="pubmed">28644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Damkier P, Lassen D, Christensen MMH, et al.. Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol. 2019;124(1):28-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30326170</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>